News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Batu Biologics Announces FDA Development Plans For ValloVax™ Angiogenesis-Targeting Cancer Vaccine


6/9/2014 8:35:35 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO--(BUSINESS WIRE)--Batu Biologics announced today FDA development plans for its patent-pending lead product, ValloVax™, a cancer immunotherapeutic “vaccine” that specifically targets the tumor blood vessels (endothelium). The vaccine is a “therapeutic vaccine” in that it will be used to stimulate the immune system of patients that already suffer from cancer. This is in contrast to conventional vaccines which are prophylactic, meaning that they are administered to prevent onset of disease.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES